
Danish pharmaceutical firm Novo Nordisk has submitted a label expansion application for its diabetes drug Ozempic to the US Food and Drug Administration (FDA), according to a company press release.
The application aims at an approval of Ozempic for the treatment of type II diabetes with a dose of 2.0 mg, building on top of the 0.5 mg and 1.0 mg which have already been approved.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app